Dengue is a mosquito-borne disease of public health importance. It is caused by four serotypes of Dengue virus (i.e, DENV-1, -2, -3, and -4). As a result of practices that are conducive for mosquito breading, its vector is widespread in Nigeria and this could result to possible DENV outbreaks in Nigeria and beyond. This study aimed to assess the recency of DENV infection as well as occurrence of DENV and Malaria co-infections within Ilorin, Nigeria. Blood samples were obtained from 176 febrile subjects and analyzed using Enzyme Linked Immunosorbent Assay (ELISA) for the presence of DENV antibodies. Malaria infection was detected using a rapid diagnostic test kit for malaria parasites. Malaria and DENV (IgM positive) co-infected samples were further subjected to RT-qPCR analysis. A seroprevalence of 46.0% was recorded for anti-DENV IgM antibodies and 2.84% for concurrent Dengue and malaria infections. Out of 95 IgM negative samples, 48 were found to be positive for DENV IgG antibodies. Eleven (6.25%) samples were confirmed DENV positive following RT-qPCR. The CT values of the amplicons were between 19.0 and 20.0. DENV serotype 2 dominated the study, while serotype 3 and 4 were equally distributed. Based on the high seroprevalence of DENV obtained in this study, there is a high possibility of experiencing Dengue virus outbreak in Ilorin, Nigeria, not neglecting the fast geographical spread of the vector. Therefore, surveillance and intensive vector control program should be instituted.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmv.24788DOI Listing

Publication Analysis

Top Keywords

dengue virus
12
denv
9
febrile subjects
8
ilorin nigeria
8
malaria
6
dengue
5
nigeria
5
virus malaria
4
malaria concurrent
4
concurrent infection
4

Similar Publications

Rapid urbanization and migration in Latin America have intensified exposure to insect-borne diseases. Malaria, Chagas disease, yellow fever, and leishmaniasis have historically afflicted the region, while dengue, chikungunya, and Zika have been described and expanded more recently. The increased presence of synanthropic vector species and spread into previously unaffected areas due to urbanization and climate warming have intensified pathogen transmission risks.

View Article and Find Full Text PDF

Equipmentless point-of-care testing of dengue antibodies using ELISA and smartphones.

J Pharm Biomed Anal

January 2025

INTEC (Universidad Nacional del Litoral-CONICET), Predio CCT CONICET-Santa Fe, RN 168, Santa Fe S3000GLN, Argentina. Electronic address:

Infections with the dengue virus affect more than 100 million people every year. The infected can present a mild form of the disease or a severe form, which can, eventually, lead to death. Dengue prevails in tropical and subtropical regions, although increased incidence has been observed in the last years in tempered climates.

View Article and Find Full Text PDF

Simultaneous Blockade of CD209 and CD209L by Monoclonal Antibody Does Not Provide Sufficient Protection Against Multiple Viral Infections In Vivo.

Immunology

January 2025

The Key Laboratory for Human Disease Gene Study of Sichuan Province, Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Many virus species, including Ebola virus, Marburg virus, SARS-CoV-2, dengue virus (DENV) and Zika virus (ZIKV), exploit CD209 and CD209L as alternative or attachment receptors for viral cis- or trans-infection. Thus, CD209 and CD209L may be critical targets for the development of therapeutic monoclonal blocking antibody drugs to disrupt the infection process caused by multiple viruses. Here, we produced a human chimeric monoclonal blocking antibody that simultaneously blocks CD209 and CD209L, namely 7-H7-B1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!